ACCOUNTS - Final Accounts preparation

Caseware UK (AP4) 2020.0.247 2020.0.247 2021-12-312021-12-31falseHolding companytrue2021-01-192falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 13145253 2021-01-18 13145253 2021-01-19 2021-12-31 13145253 2020-01-01 2021-01-18 13145253 2021-12-31 13145253 c:Director1 2021-01-19 2021-12-31 13145253 c:Director2 2021-01-19 2021-12-31 13145253 d:CurrentFinancialInstruments 2021-12-31 13145253 d:CurrentFinancialInstruments d:WithinOneYear 2021-12-31 13145253 d:ShareCapital 2021-12-31 13145253 d:SharePremium 2021-12-31 13145253 d:RetainedEarningsAccumulatedLosses 2021-12-31 13145253 c:FRS102 2021-01-19 2021-12-31 13145253 c:AuditExempt-NoAccountantsReport 2021-01-19 2021-12-31 13145253 c:FullAccounts 2021-01-19 2021-12-31 13145253 c:PrivateLimitedCompanyLtd 2021-01-19 2021-12-31 13145253 6 2021-01-19 2021-12-31 iso4217:GBP xbrli:pure

Registered number: 13145253

ERGENIX LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2021

ERGENIX LIMITED

REGISTERED NUMBER: 13145253

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2021

		2021
Note		£

Fixed assets
Investments		804,002
		804,002

Creditors: amounts falling due within one year	(405,852)
Net current (liabilities)/assets		(405,852)
Total assets less current liabilities		398,150

Net assets		398,150

Capital and reserves
Called up share capital			50
Share premium account			399,900
Profit and loss account			(1,800)
			398,150

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Mr Gagan Kumar Jairath	Mr Zaheer Mohammed
Director	Director

Date: 8 September 2022

The notes on pages 3 to 4 form part of these financial statements.

Page 1

ERGENIX LIMITED

REGISTERED NUMBER: 13145253

STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 DECEMBER 2021

Page 2

ERGENIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2021

1.	General information

Ergenix Limited is a private company, limited by share capital, incorporated in England and Wales under registration number 13145253. The address of the registered office of the company is situated at 16 - 20 St Augustines Gate, Hedon, Hull, East Ridings of Yorkshire, HU12 8EX.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Profit and loss account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Employees

The average monthly number of employees, including directors, during the period was 2.

Page 3

ERGENIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2021

4.	Fixed asset investments

		Unlisted investments
		£
	Cost or valuation
	Additions	804,002
	At 31 December 2021	804,002

The company owns 100% issued share capital of Caring Nationwide Limited and Faith Pharma Limited.

5.	Creditors: Amounts falling due within one year
		2021
		£

	Amounts owed to subsidiary company	404,000
	Directors loan account	52
	Accruals and deferred income	1,800
		405,852

6.	Controlling party

The company was under the control of Mr Gagan Kumar Jairath (50% share) and Mr Zaheer Mohammed (30% share), by virtue of the fact that between them they own 80% of the issued share capital of the company.

Page 4